Clinically, patients with HER2+ breast cancer had significantly increased PD-L1 and IDO expression in tumor-infiltrating macrophages after preoperative treatment with trastuzumab, which determined response to trastuzumab (58). This evidence concerns the gene ERBB2 and breast cancer.